{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T07:40:53Z","timestamp":1774165253394,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Risk-reducing salpingo-oophorectomy is performed for the primary prevention of ovarian cancer in patients with hereditary breast\u2013ovarian cancer syndrome. We performed risk-reducing salpingo-oophorectomy for the first time in Japan in 2008, and we experienced 20 cases of risk-reducing salpingo-oophorectomy through 2019. In the past, the use of risk-reducing salpingo-oophorectomy in Japan was restricted because it was not covered by a Japanese National Health Insurance. Since April 2020, risk-reducing salpingo-oophorectomy has been covered by insurance for patients with breast\u2013ovarian cancer syndrome and pre-existing breast cancer, and this surgery is expected to become more widely implemented in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To contribute to the widespread use of risk-reducing salpingo-oophorectomy in the future, we retrospectively reviewed 20 cases of risk-reducing salpingo-oophorectomy at our hospital cohort study to clarify the issues in its implementation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The variant genes for which risk-reducing salpingo-oophorectomy was indicated were BRCA1 and BRCA2 in 13 (65%) and 7 patients (35%), respectively. The median age at which risk-reducing salpingo-oophorectomy was performed was 49\u00a0years (range, 38\u201358), 13 patients (65%) had gone through menopause, and 16 patients (80%) had a history of breast cancer. Of the five patients (25%) with vasomotor symptoms, four received Chinese medicine, and only one received hormone replacement therapy. Occult cancer was detected in the removed ovaries in two patients (10%), although no postoperative peritoneal carcinogenesis has been observed to date.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Women who paid for risk-reducing salpingo-oophorectomy out of pocket were older than the recommended age at which the procedure should be performed, and this may explain the higher rate of occult cancers than previously reported. We need to perform risk-reducing salpingo-oophorectomy at the recommended age to ensure that the procedure is effective for primary prevention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa173","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T11:11:05Z","timestamp":1598526665000},"page":"213-217","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective evaluation of risk-reducing salpingo-oophorectomy for <i>BRCA1\/2<\/i> pathogenic variant carriers among a cohort study in a single institution"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-2845","authenticated-orcid":false,"given":"Yusuke","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"},{"name":"Center for Medical Genetics, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hirasawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"},{"name":"Center for Medical Genetics, Keio University School of Medicine, Tokyo"},{"name":"Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Ueki","sequence":"additional","affiliation":[{"name":"Center for Medical Genetics, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Misu","sequence":"additional","affiliation":[{"name":"Center for Medical Genetics, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kawaida","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology, Keio University Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigenori","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"},{"name":"Department of Obstetrics and Gynecology, International University of Health and Welfare School of Medicine, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kosaki","sequence":"additional","affiliation":[{"name":"Center for Medical Genetics, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8326","authenticated-orcid":false,"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"2021020810263048700_ref1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"2021020810263048700_ref2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2021020810263048700_ref3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"2021020810263048700_ref4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"2021020810263048700_ref5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021020810263048700_ref6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021020810263048700_ref7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021020810263048700_ref8"},{"key":"2021020810263048700_ref9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12282-017-0803-y","article-title":"Cost-effectiveness of surveillance and prevention strategies in BRCA1\/2 mutation carriers","volume":"25","author":"Yamauchi","year":"2018","journal-title":"Breast Cancer"},{"key":"2021020810263048700_ref10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jjco\/hyt036","article-title":"Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future","volume":"43","author":"Hirasawa","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2021020810263048700_ref11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/modpathol.2013.212","article-title":"M\u00fcllerian precursor lesions in serous ovarian cancer patients: using the SEE-FIM and SEE-END protocol","volume":"27","author":"Mingels","year":"2014","journal-title":"Mod Pathol"},{"key":"2021020810263048700_ref12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jjco\/hyt171","article-title":"Family history and BRCA1\/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case","volume":"44","author":"Hirasawa","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2021020810263048700_ref13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","article-title":"Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","volume":"148","author":"Chai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2021020810263048700_ref14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00432-015-2051-x","article-title":"Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea","volume":"142","author":"Kim","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021020810263048700_ref15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10147-019-01456-4","article-title":"Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan","volume":"24","author":"Nomura","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2021020810263048700_ref16","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021020810263048700_ref17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021020810263048700_ref18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021020810263048700_ref19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ygyno.2017.03.025","article-title":"Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous\/serous-like uterine cancers in BRCA1 mutation carriers","volume":"145","author":"Havrilesky","year":"2017","journal-title":"Gynecol Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/2\/213\/36212682\/hyaa173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/2\/213\/36212682\/hyaa173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:17:46Z","timestamp":1612815466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/2\/213\/5919788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,10]]},"published-print":{"date-parts":[[2021,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa173","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,10,10]]}}}